Parallel Review: End Of Phase II Could Be Best Time For CMS Involvement
Executive Summary
Assuming FDA and CMS move forward with their plan to start parallel reviews of medical products, the end of Phase II trials may be the best time for CMS to start having input in the clinical development process for drugs, a CMS official suggested.
You may also be interested in...
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.
FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say
As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.